Growth factors VEGF and TGF-β1 in peritoneal dialysis

Zweers, Machteld M.; Waart, Dirk R. de; Smit, Watske; Struijk, Dirk G.; Krediet, Raymond T.

doi:10.1016/s0022-2143(99)90116-6

Cited by 169 publications

(160 citation statements)

References 23 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…In addition, the correlation coefficient between the drainage levels of MMP-2 and TIMP-1 was higher than that between the drainage levels of MMP-2 and MMP-3 [26]. The difference between the measured D/S ratio and the predicted ratio may be attributable to the local production of MMP-2 and TIMP-1 in the peritoneal tissue along with their transport from the circulation [28]. In addition, MMP-1 and TIMP-2 were not detected in the peritoneal effluent of most patients.…”

Section: Mmps As Peritoneal Injury Markers In Clinical Diagnosismentioning

confidence: 85%

Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Hirahara¹,

Akimoto²,

Morishita³

et al. 2011

Progress in Peritoneal Dialysis

View full text Add to dashboard Cite

Section: Mmps As Peritoneal Injury Markers In Clinical Diagnosismentioning

confidence: 85%

Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Hirahara¹,

Akimoto²,

Morishita³

et al. 2011

Progress in Peritoneal Dialysis

View full text Add to dashboard Cite

“…An endothelial cell mitogen and potent angiogenic factor, VEGF is produced in the peritoneum during PD treatment with glucose-based PD solutions, and then it undergoes endothelial upregulation along the peritoneal blood vessels in long-term PD (8,10,11). This implies that VEGF activation may play a role during the progression of PF and that inhibition of VEGF may reduce fibrosis as well as angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Expression studies on this growth factor have demonstrated that long-term exposure to glucose-based PD solution induces a clear upregulation of VEGF expression (8,9,10). Such studies have also detected abundant amounts of VEGF in dialysate, which is directly associated with small solute permeability and impaired UF capacity (11). Therefore, with reference to other angiogenic conditions, upregulation of VEGF expression is argued to have a potential to induce vascular proliferation in the peritoneal membrane in patients receiving long-term PD treatment (12).…”

Section: Introductionmentioning

confidence: 99%

“…Evidence from clinical studies indicates TGF-β1 presence in the peritoneum, which is up-regulated during episodes of peritonitis. Elevated levels of TGF-β1 in dialysate concentrations have been shown to be associated with poorer outcomes in PD patients (8,9,17).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Mycophenolate Mofetil and Rapamycin on Peritoneal Fibrosis in an Experimental Model of Peritoneal Dialysis

Dursun¹,

Noyan²,

Erdoğan³

et al. 2015

Turk Neph Dial Transpl

View full text Add to dashboard Cite

OBJEcTIVE: This study aimed to investigate the effect of mycophenolate mofetil and rapamycin on peritoneal function and morphology in a rat model of experimental peritoneal dialysis. MATERIAL and METHODS:A total of 60 male Albino rats (Wistar strain) were equally divided into four groups as follows: Mycophenolate mofetil group (MMFG), rapamycin group (RAPG) and no-treatment group (NTG) receiving 15 mL 3.86% glucose solution, and control group (CG) receiving daily intraperitoneal injection of 15 mL normal saline. Mycophenolate mofetil and rapamycin were administered orally via daily gastric gavage in MMFG and RAPG. We conducted one-hour peritoneal equilibration tests at 8 weeks, measuring ultrafiltration, serum and dialysate growth factors and cytokines. Peritoneal membrane morphology was examined under the light microscope. RESULTS:Compared to controls, levels of serum and dialysate vascular endothelial growth factor were significantly higher in NTG (p<0.05), but they did not differ significantly in MMFG and RAPG (p>0.05). Net ultrafiltration was significantly higher in MMFG than in NTG (p<0.05). A significant decline was detected in the number of mesothelial, inflammatory and fibroblast cells and peritoneal membrane thickness in MMFG, as compared with NTG. cONcLUSION:We conclude that peritoneal functions such as ultrafiltration capacity can be protected by treatment with MMF and RAP, as they produce a membrane-protective effect in peritoneal dialysis. KEY wORDS:Experimental peritoneal dialysis, Mycophenolate mofetil, Peritoneal fibrosis, Rapamycin, Rat ÖZ AMAÇ: Çalışmanın amacı deneysel bir sıçan periton diyaliz modelinde mikofenolat mofetil ve rapamisinin periton fonksiyonu ve morfolojisi üzerine etkisini araştırmaktır. GEREÇ ve YÖNTEMLER:Wistar-Albino 60 sıçan 4 eşit gruba ayrıldı: Mikofenolat mofetil grubu (MMFG), rapamisin grubu (RAPG) ve tedavi almayan grubu (NTG) %3,86 glikozlu solüsyonundan 15 mL ve kontrol grubu (CG) normal izotonik sıvıdan 15 mL günde tek doz intraperitoneal enjeksiyonla aldı. MMFG ve RAPG günlük gastrik gavajla sırasıyla mikofenolat mofetil ve rapamisin aldılar. Sekiz hafta sonunda 1 saatlik bir periton eşitleme testi yapıldı. Ultrafiltrasyon, serum ve diyalizatta büyüme faktörleri ve sitokinler ölçüldü. Periton membran morfolojisi ışık mikroskopisi ile değerlendirildi.BULGULAR: Serum ve diyalizat vasküler endotelyal büyüme faktör düzeyleri CG ile karşılaştırıl-dığında NTG da anlamlı oranda daha yüksek saptandı (p<0,05), fakat MMFG ve RAPG gruplarında anlamlı fark saptanmadı (p>0,05). Net ultrafiltrasyon NTG'la karşılaştırıldığında MMFG'da anlamlı oranda daha yüksekti (p<0,05). NTG ile karşılaştırıldığında mezotelyal, inflamatuvar ve fibroblast hücre sayısı ile periton membran kalınlığı MMFG'da anlamlı oranda daha düşük saptandı. SONUÇ:Ultrafiltrasyon gibi periton fonksiyonlarının MMF ve RAP ile korunduğu ve bu ilaçların periton diyalizinde periton membranını koruyucu etkiye sahip oldukları sonucuna vardık.

show abstract

The Corticotropin Releasing Factor System in the Kidney: Perspectives for Novel Therapeutic Intervention in Nephrology

Devetzis

Kakolyris

Vargemezis

et al. 2012

Medicinal Research Reviews

View full text Add to dashboard Cite

The adaptation to endogenous and exogenous stress stimuli is crucial for survival but also for the onset of various diseases in humans. Corticotropin releasing factor (CRF) system is the major regulator of stress response and homeostasis. The members of this family of peptides extend their actions also outside CNS to the periphery where they may affect various body systems independently, acting via vagal and/or autocrine/paracrine pathways. In search for peripheral targets, kidney has rarely been studied separately, regarding expression and action of CRF and CRF-related peptides. We reviewed the existing literature concerning expression and action of the CRF system in normal and pathological renal tissue and explored possible clinical implications in nephrology. CRF system components are expressed in the kidney of experimental animals and in humans. The intrarenal distribution is reported to be equally extensive, suggesting a physiological or pathophysiological role in renal function and in the occurrence of renal disease. Urocortins have given multiple interesting observations in experimental models of renal disease and clinical studies, showing robust effects in renal regulation mechanisms. We summarize the relevant data and put them in context, proposing applications with clinical significance in the field of hypertension, diabetic nephropathy, chronic kidney disease, cardiorenal syndrome, and peritoneal dialysis.

show abstract

Growth factors VEGF and TGF-β1 in peritoneal dialysis

Cited by 169 publications

References 23 publications

Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Effects of Mycophenolate Mofetil and Rapamycin on Peritoneal Fibrosis in an Experimental Model of Peritoneal Dialysis

The Corticotropin Releasing Factor System in the Kidney: Perspectives for Novel Therapeutic Intervention in Nephrology

Contact Info

Product

Resources

About

Growth factors VEGF and TGF-β1 in peritoneal dialysis

Cited by 169 publications

References 23 publications

Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Matrix Metalloproteinases Cause Peritoneal Injury in Peritoneal Dialysis

Effects of Mycophenolate Mofetil and Rapamycin on Peritoneal Fibrosis ￼in an Experimental Model of Peritoneal Dialysis

The Corticotropin Releasing Factor System in the Kidney: Perspectives for Novel Therapeutic Intervention in Nephrology

Contact Info

Product

Resources

About

Effects of Mycophenolate Mofetil and Rapamycin on Peritoneal Fibrosis in an Experimental Model of Peritoneal Dialysis